- Home
- EPSM vs SKYE Comparison
EPSM vs SKYE Comparison
Compare EPSM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSM
- SKYE
- Stock Information
- Founded
- EPSM 2010
- SKYE 2012
- Country
- EPSM China
- SKYE United States
- Employees
- EPSM N/A
- SKYE N/A
- Industry
- EPSM
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- EPSM
- SKYE Health Care
- Exchange
- EPSM Nasdaq
- SKYE Nasdaq
- Market Cap
- EPSM 185.6M
- SKYE 80.7M
- IPO Year
- EPSM 2025
- SKYE N/A
- Fundamental
- Price
- EPSM $15.77
- SKYE $1.98
- Analyst Decision
- EPSM
- SKYE Buy
- Analyst Count
- EPSM 0
- SKYE 6
- Target Price
- EPSM N/A
- SKYE $16.60
- AVG Volume (30 Days)
- EPSM 517.6K
- SKYE 223.6K
- Earning Date
- EPSM 01-01-0001
- SKYE 05-08-2025
- Dividend Yield
- EPSM N/A
- SKYE N/A
- EPS Growth
- EPSM N/A
- SKYE N/A
- EPS
- EPSM 0.02
- SKYE N/A
- Revenue
- EPSM $12,518,070.00
- SKYE N/A
- Revenue This Year
- EPSM N/A
- SKYE N/A
- Revenue Next Year
- EPSM N/A
- SKYE N/A
- P/E Ratio
- EPSM $771.01
- SKYE N/A
- Revenue Growth
- EPSM N/A
- SKYE N/A
- 52 Week Low
- EPSM $4.23
- SKYE $1.14
- 52 Week High
- EPSM $17.63
- SKYE $12.11
- Technical
- Relative Strength Index (RSI)
- EPSM N/A
- SKYE 50.21
- Support Level
- EPSM N/A
- SKYE $1.88
- Resistance Level
- EPSM N/A
- SKYE $2.28
- Average True Range (ATR)
- EPSM 0.00
- SKYE 0.23
- MACD
- EPSM 0.00
- SKYE 0.00
- Stochastic Oscillator
- EPSM 0.00
- SKYE 40.00
About EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.